ZyVersa Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZVSA research report →
Price Chart
About the company
ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease.
- CEO
- Stephen C. Glover
- IPO
- 2022
- Employees
- 6
- HQ
- Weston, FL, US
Get TickerSpark's AI analysis on ZVSA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $810
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.06
- EV/EBITDA
- -36.34
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.79%
- ROIC
- -16.53%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-6,844,787
- Net Income
- $-24,952,378+99.7%
- EPS
- $-4.18+50.7%
- OCF Growth
- +32.3%
- FCF Growth
- +32.3%
- 52W High
- $0.30
- 52W Low
- $0.00
- 50D MA
- $0.04
- 200D MA
- $0.14
- Beta
- 0.84
- RSI (14)
- 16
- Avg Volume
- 8.39K
No earnings-call transcripts are available for ZVSA yet.
- Free Float
- 60.7%
- Shares Outstanding
- 8.10M
- Float Shares
- 4.92M
of shares held by institutions
6 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Guerra Advisors Inc | 7 | ▲ 7 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 11, 25 | Cashmere Karen A. | other | 48,100 |
| Jul 11, 25 | Freitag Gregory Gene | other | 11,066 |
| Jul 11, 25 | Glover Stephen C. | other | 136,900 |
| Jul 11, 25 | Finizio Robert G | other | 11,066 |
| Jul 11, 25 | Wolfe Peter | other | 60,100 |
| Jul 11, 25 | Guzman Pablo A. | other | 48,900 |
| Jul 11, 25 | Park Min-Chul | other | 11,066 |
| Jul 11, 25 | SAPIRSTEIN JAMES | other | 11,066 |
| May 24, 23 | Cashmere Karen A. | other | 572 |
| May 24, 23 | Wolfe Peter | other | 715 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ZVSA coverage
Recent articles, reports, and earnings notes.
No research on ZVSA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZVSA report →ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · May 13
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · May 13
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
globenewswire.com · Mar 31
ZyVersa Therapeutics (NASDAQ:ZVSA) Shares Up 65.4% – Still a Buy?
defenseworld.net · Jan 10
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
globenewswire.com · Nov 19
ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes
globenewswire.com · Sep 10
ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression
globenewswire.com · Sep 3
ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression
globenewswire.com · Aug 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.